ArticleInfection and immunity2008
Oral vaccination against bubonic plague using a live avirulent Yersinia pseudotuberculosis strain.
Article in Infection and immunity, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 40 citations in OpenAlex.
- Protection Induced by Oral Vaccination with a RecombinantInfection and immunity · 2022Article
- Human gut-associated lymphoid tissues (GALT); diversity, structure, and function.Mucosal immunology · 2021Review
- Bread Feeding Is a Robust and More Physiological Enteropathogen Administration Method Compared to Oral Gavage.Infection and immunity · 2020Article
- A Recombinant AttenuatedInfection and immunity · 2019Article
- Article
- Chemical Modification of Chitosan for Efficient Vaccine Delivery.Molecules (Basel, Switzerland) · 2018Review
- A study on the efficacy of the recombinant Yersinia adhesin A vaccine against yersiniosis in the early phase.The Journal of veterinary medical science · 2017Article
- Plague Vaccine Development: Current Research and Future Trends.Frontiers in immunology · 2016Review
- Plague Vaccines: Status and Future.Advances in experimental medicine and biology · 2016Review
- Oral administration of a recombinant attenuated Yersinia pseudotuberculosis strain elicits protective immunity against plague.Vaccine · 2015Article
- Complete Protection against Pneumonic and Bubonic Plague after a Single Oral Vaccination.PLoS neglected tropical diseases · 2015Article
- LcrV delivered via type III secretion system of live attenuated Yersinia pseudotuberculosis enhances immunogenicity against pneumonic plague.Infection and immunity · 2014Article
- An encapsulated Yersinia pseudotuberculosis is a highly efficient vaccine against pneumonic plague.PLoS neglected tropical diseases · 2012Article
- A protective epitope in type III effector YopE is a major CD8 T cell antigen during primary infection with Yersinia pseudotuberculosis.Infection and immunity · 2012Article
- Developing live vaccines against plague.Journal of infection in developing countries · 2011Review
- Principles of antidote pharmacology: an update on prophylaxis, post-exposure treatment recommendations and research initiatives for biological agents.British journal of pharmacology · 2010Review
- Protection against pneumonic plague following oral immunization with a non-replicating vaccine.Vaccine · 2010Article
- The smpB-ssrA mutant of Yersinia pestis functions as a live attenuated vaccine to protect mice against pulmonary plague infection.Infection and immunity · 2010Article
- Humoral immune responses and protective efficacy of sequential B- and T-cell epitopes of V antigen of Yersinia pestis by intranasal immunization in microparticles.Medical microbiology and immunology · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We evaluated the possibility of using Yersinia pseudotuberculosis as a live vaccine against plague because it shares high genetic identity with Y. pestis while being much less virulent, genetically much more stable, and deliverable orally. A total of 41 Y. pseudotuberculosis strains were screened by PCR for the absence of the high pathogenicity island, the superantigens YPM, and the type IV pilus and the presence of the pYV virulence plasmid. One strain (IP32680) fulfilled these criteria. This strain was avirulent in mice upon intragastric or subcutaneous inoculation and persisted for 2 months in the mouse intestine without clinical signs of disease. IP32680 reached the mesenteric lymph nodes, spleen, and liver without causing major histological lesions and was cleared after 13 days. The antibodies produced in vaccinated animals recognized both Y. pseudotuberculosis and Y. pestis antigens efficiently. After a subcutaneous challenge with Y. pestis CO92, bacteria were found in low amounts in the organs and rarely in the blood of vaccinated animals. One oral IP32680 inoculation protected 75% of the mice, and two inoculations induced much higher antibody titers and protected 88% of the mice. Our results thus validate the concept that an attenuated Y. pseudotuberculosis strain can be an efficient, inexpensive, safe, and easy-to-produce live vaccine for oral immunization against bubonic plague.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.